Peptide Receptor Radionuclide Therapy – Prospects for Personalised Treatment

Peptide receptor radionuclide therapy is a type of molecular radiotherapy that has been used in the treatment patients with neuroendocrine tumours for over two decades. It not until recently, however, it achieved regulatory approval. The currently approved regimen one-size-fits-all scheme, i.e. all receive fixed activity radiopharmaceutical (177Lu-DOTATATE) and number cycles. Several research groups around world have studied different approaches further improving on results peptide therapy, many promising retrospective prospective clinical studies having published years. In this overview, we summarise some most strategies identified so far.